Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 16Neoplasms 6Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Advanced Malignant Solid Tumors 3Lung Neoplasms 2Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1HER2+ Metastatic Breast Cancer (MBC) 1Cholangiocarcinoma 1Brain Neoplasms 1

Interventions

pembrolizumab 3entrectinib 2zanidatamab 1trastuzumab deruxtecan 1spartalizumab 1neratinib 1larotrectinib 1cevimeline 1apalutamide 1alectinib 1Tablets 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy 1Gonadotropin-Releasing Hormone 1Fentanyl 1EBC-46 1Drug Therapy 1Docetaxel 1Combined Modality Therapy 1Carboplatin 1Biological Therapy 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Salivary Gland Neoplasms × neratinib × Clear all
NCT06519110 2024-07-25

CVL009-C2001

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
60 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Salivary Gland Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡